Overview

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

Status:
Recruiting

Trial end date:
2024-03-28

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in patients with recurrent or metastatic head and neck cancer.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Innate Pharma

Treatments:

Cetuximab